PL2030622T3 - Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu - Google Patents

Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu

Info

Publication number
PL2030622T3
PL2030622T3 PL08167618T PL08167618T PL2030622T3 PL 2030622 T3 PL2030622 T3 PL 2030622T3 PL 08167618 T PL08167618 T PL 08167618T PL 08167618 T PL08167618 T PL 08167618T PL 2030622 T3 PL2030622 T3 PL 2030622T3
Authority
PL
Poland
Prior art keywords
progesterone
dosage
indication
treatment
brain injury
Prior art date
Application number
PL08167618T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellerman
Donald G Stein
David W Wright
Douglas W Lowery-North
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of PL2030622T3 publication Critical patent/PL2030622T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL08167618T 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu PL2030622T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
EP08167618A EP2030622B1 (en) 2005-03-24 2006-03-24 Indication of dosage of progesterone in the treatment of a traumatic brain injury
EP06748657A EP1868614B1 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone

Publications (1)

Publication Number Publication Date
PL2030622T3 true PL2030622T3 (pl) 2011-07-29

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08167618T PL2030622T3 (pl) 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu
PL06748657T PL1868614T3 (pl) 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06748657T PL1868614T3 (pl) 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem

Country Status (15)

Country Link
US (4) US20090325920A1 (pl)
EP (5) EP1871382B1 (pl)
JP (5) JP5295755B2 (pl)
AT (2) ATE499104T1 (pl)
AU (2) AU2006226774B2 (pl)
CA (2) CA2601715C (pl)
CY (2) CY1111478T1 (pl)
DE (1) DE602006020353D1 (pl)
DK (2) DK2030622T3 (pl)
ES (2) ES2392454T3 (pl)
HR (2) HRP20120688T1 (pl)
PL (2) PL2030622T3 (pl)
PT (2) PT2030622E (pl)
RS (1) RS52471B (pl)
WO (2) WO2006102596A2 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE499104T1 (de) * 2005-03-24 2011-03-15 Univ Emory Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
CA2955684A1 (en) 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
RU2366466C1 (ru) * 2008-03-25 2009-09-10 Олег Васильевич Онысько Способ лечения черепно-мозговой травмы
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10231976B2 (en) 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
MX357761B (es) * 2011-04-27 2018-07-23 Univ Northwestern Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
NO2819649T3 (pl) 2012-02-29 2018-06-09
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
JP6419087B2 (ja) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
SG11201505937SA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
CN105308049A (zh) 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2015023593A1 (en) 2013-08-12 2015-02-19 Emory University Progesterone phosphate analogs and uses related thereto
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
CN113366318A (zh) * 2019-01-31 2021-09-07 日内瓦大学 创伤性脑损伤(tbi)的前瞻性标志物
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
AU2022401678A1 (en) * 2021-12-02 2024-07-04 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
US20230293722A1 (en) * 2022-01-05 2023-09-21 Metaqor Llc Compositions and Methods for Treating Neurological-associated Disorders
US20260091055A1 (en) * 2022-09-12 2026-04-02 Emory University Methods of Managing Traumatic Brain Injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0382790A4 (en) 1987-08-25 1991-03-27 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
PT1382340E (pt) * 1993-01-19 2006-07-31 Endorech Inc Utilizacoes terapeuticas de desidroepiandrosterona para tratar libido diminuida e osteoporose
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
PT837874E (pt) * 1995-06-06 2005-03-31 Euro Celtique Sa Esteroides neuroactivos da serie androstano e pregnano
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
IL127189A0 (en) 1996-05-22 1999-09-22 Diversified Pharmaceuticals In Compositions methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
CN1254283A (zh) 1997-05-02 2000-05-24 美国家用产品公司 孕烷－3－醇－20－酮
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
ATE499104T1 (de) * 2005-03-24 2011-03-15 Univ Emory Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns

Also Published As

Publication number Publication date
CA2601715A1 (en) 2006-09-28
ES2392454T3 (es) 2012-12-10
HRP20120688T1 (hr) 2012-09-30
WO2006102644A2 (en) 2006-09-28
US20090221544A1 (en) 2009-09-03
DE602006020353D1 (de) 2011-04-07
JP5295755B2 (ja) 2013-09-18
US20090325920A1 (en) 2009-12-31
DK1868614T3 (da) 2012-11-12
EP1868614B1 (en) 2012-08-08
CA2601715C (en) 2012-10-16
DK2030622T3 (da) 2011-05-02
JP2014055183A (ja) 2014-03-27
WO2006102596A3 (en) 2007-01-18
US20120289491A1 (en) 2012-11-15
EP2431042A1 (en) 2012-03-21
EP1871382A2 (en) 2008-01-02
ATE520404T1 (de) 2011-09-15
CY1111478T1 (el) 2015-08-05
JP2008534515A (ja) 2008-08-28
US20120245133A1 (en) 2012-09-27
WO2006102644A9 (en) 2006-11-23
AU2006226774A1 (en) 2006-09-28
EP2494976A1 (en) 2012-09-05
AU2006226811A1 (en) 2006-09-28
PT1868614E (pt) 2012-11-23
HK1112581A1 (en) 2008-09-12
CA2602950C (en) 2012-10-30
ES2428313T3 (es) 2013-11-07
PT2030622E (pt) 2011-06-02
EP2030622A1 (en) 2009-03-04
WO2006102644A3 (en) 2007-03-01
WO2006102596A2 (en) 2006-09-28
ATE499104T1 (de) 2011-03-15
EP1871382B1 (en) 2011-08-17
US8614203B2 (en) 2013-12-24
JP5496407B2 (ja) 2014-05-21
HK1128242A1 (en) 2009-10-23
JP5394059B2 (ja) 2014-01-22
EP2431042B1 (en) 2013-06-26
RS52471B (sr) 2013-02-28
CY1113253T1 (el) 2016-04-13
AU2006226811B2 (en) 2010-11-25
HRP20110198T1 (hr) 2011-04-30
JP2011225629A (ja) 2011-11-10
HK1112579A1 (en) 2008-09-12
EP2030622B1 (en) 2011-02-23
AU2006226774B2 (en) 2010-12-02
EP1868614A2 (en) 2007-12-26
CA2602950A1 (en) 2006-09-28
PL1868614T3 (pl) 2013-01-31
JP2013234191A (ja) 2013-11-21
JP2008534512A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
PT2030622E (pt) Indicação da dose de progesterona no tratamento de um traumatismo crânio-encefálico
Deutsch et al. Progesterone's role in neuroprotection, a review of the evidence
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
WO2012106444A3 (en) Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
PL1976886T3 (pl) Środki i metody do leczenia chorób nowotworowych
TW200740804A (en) Glucokinase activators
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
IL163752A0 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
SI1913947T1 (sl) Kombinirana terapija za zdravljenje raka
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
PL1704860T3 (pl) Pochodne benzamidyny do leczenia i zapobiegania zapaleniu śluzówki
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
Axelrod et al. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model
WO2009041573A1 (ja) 頭頚部癌の治療に用いる、腫瘍栄養動脈に投与される抗癌細胞組成物の使用
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
Fourianalistyawati et al. The Effectiveness of Mindfulness Technique to Decrease Pain in University Students
Chefranova et al. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke
EP4447955A4 (en) USE OF HYPERPOLARIZING AGENTS ALONE AND IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCERS INCLUDING A GLIOBLASTOMA
WO2005120489A3 (en) Treatment of central nervous system disorders or injuries with d-methionine